Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022 Obe-cel: 35% of relapsed/refractory adult B-ALL patients in the ALLCAR19 trial remain in complete remission at a median follow up of three years without the need for additional anti-leukemia...

UM171 cell therapy demonstrates improved outcomes compared to cord and matched unrelated donor peripheral blood transplants in real-world setting MONTRÉAL, Dec. 12, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today findings from a safety and efficacy...

Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022 SOUTH SAN FRANCISCO, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...

ExCellThera announces oral presentation of new data on UM171-expanded cell therapy at the ASH Annual Meeting MONTREAL, Nov. 04, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that an abstract related to ExCellThera’s...

Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022 obe-cel: poster presentation in B-ALL and B-NHL patientsAUTO1/22: poster presentation in pediatric ALL patientsAUTO4: poster presentation in T-Cell Lymphoma patients LONDON, Nov. 03, 2022 ...